利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.019 秒)

    Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
    12.
    发明授权
    Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof 有权

    公开(公告)号：US11633501B2

    公开(公告)日：2023-04-25

    申请号：US16992453

    申请日：2020-08-13

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： John Rudge ,  Frank Delfino ,  Lauric Haber ,  Eric Smith ,  Jessica R. Kirshner ,  Alison Crawford ,  Thomas Nittoli

    IPC分类号： A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C07K16/40 ,  C07K16/46 ,  A61K39/00

    摘要： The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.

    Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
    15.
    发明授权
    Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof 有权

    公开(公告)号：US10772972B2

    公开(公告)日：2020-09-15

    申请号：US15713569

    申请日：2017-09-22

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： John Rudge ,  Frank Delfino ,  Lauric Haber ,  Eric Smith ,  Jessica R. Kirshner ,  Alison Crawford ,  Thomas Nittoli

    IPC分类号： A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C07K16/40 ,  C07K16/46 ,  A61K39/00

    摘要： The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human STEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.

    Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
    16.
    发明授权
    Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof 有权

    公开(公告)号：US11485793B2

    公开(公告)日：2022-11-01

    申请号：US16913154

    申请日：2020-06-26

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Lauric Haber ,  Eric Smith ,  Marcus Kelly ,  Jessica R. Kirshner ,  Sandra Coetzee ,  Alison Crawford ,  Thomas Nittoli ,  Yashu Liu

    IPC分类号： C07K16/30 ,  C07K16/46 ,  A61K39/395 ,  C07K16/28 ,  C07K16/44 ,  A61K47/68 ,  G01N33/574 ,  A61K39/00

    摘要： Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced MUC16-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including ovarian cancer. The present invention also includes anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo. In some embodiments, the anti-MUC16 antibodies are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

    Anti-STEAP2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind STEAP2 and CD3, and Uses Thereof
    18.
    发明申请
    Anti-STEAP2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind STEAP2 and CD3, and Uses Thereof 审中-公开

    公开(公告)号：US20200376136A1

    公开(公告)日：2020-12-03

    申请号：US16992453

    申请日：2020-08-13

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： John Rudge ,  Frank Delfino ,  Lauric Haber ,  Eric Smith ,  Jessica R. Kirshner ,  Alison Crawford ,  Thomas Nittoli

    IPC分类号： A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C07K16/40 ,  C07K16/46

    摘要： The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
    20.
    发明授权
    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof 有权

    公开(公告)号：US10179819B2

    公开(公告)日：2019-01-15

    申请号：US15223434

    申请日：2016-07-29

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Jessica R. Kirshner ,  Alison Crawford ,  Gavin Thurston ,  Eric Smith ,  Lauric Haber ,  Drew Dudgeon ,  Ashique Rafique

    IPC分类号： A61K39/00 ,  C07K16/30 ,  C07K16/28 ,  A61K39/395

    摘要： The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.